These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

783 related items for PubMed ID: 26117292

  • 1. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 3. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM, Donald AC, O'Dell D, Church A, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct; 11():971-9. PubMed ID: 27274218
    [Abstract] [Full Text] [Related]

  • 4. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 5. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G, Walker RR, Brooks J, Mehta R, Crater G.
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [Abstract] [Full Text] [Related]

  • 6. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 7. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J, Zhong N, Newlands A, Church A, Goh AH.
    Int J Chron Obstruct Pulmon Dis; 2015 Aug; 10():1753-67. PubMed ID: 26366068
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A.
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [Abstract] [Full Text] [Related]

  • 10. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID.
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [Abstract] [Full Text] [Related]

  • 12. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan; 14():2849-2861. PubMed ID: 31839705
    [Abstract] [Full Text] [Related]

  • 13. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
    Zheng J, Zhong N, Wang C, Huang Y, Chen P, Wang L, Hui F, Zhao L, Wang H, Luo L, Du X, Han Goh A, Lipson DA.
    COPD; 2018 Jan; 15(4):334-340. PubMed ID: 30265816
    [Abstract] [Full Text] [Related]

  • 14. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L, Kerwin E, Collison K, Nelsen L, Wu W, Yang S, Pascoe S.
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 16. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.
    Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
    [Abstract] [Full Text] [Related]

  • 17. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA.
    Respir Res; 2018 Jan 25; 19(1):19. PubMed ID: 29370819
    [Abstract] [Full Text] [Related]

  • 18. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.
    Respir Med; 2015 Jul 25; 109(7):870-81. PubMed ID: 26006754
    [Abstract] [Full Text] [Related]

  • 19. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG.
    Adv Ther; 2022 Sep 25; 39(9):3957-3978. PubMed ID: 35849317
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug 25; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.